Predictors of QOL in Patients with Alopecia Areata

被引:16
|
作者
Senna, Maryanne [1 ]
Ko, Justin [2 ]
Glashofer, Marc [3 ]
Walker, Chloe [1 ]
Ball, Susan [4 ]
Edson-Heredia, Emily [4 ]
Zhu, Baojin [4 ]
Shapiro, Jerry [5 ]
机构
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[3] Dermatol Grp, W Orange, NJ USA
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] NYU, Ronald O Perelman Dept Dermatol, New York, NY USA
关键词
QUALITY-OF-LIFE;
D O I
10.1016/j.jid.2022.02.019
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Although alopecia areata (AA) severity is often defined by the degree of scalp hair loss, its impact on QOL can also be a defining measure of severity. In this cross-sectional study (AA Disease Specific Program), 259 patients were surveyed for demographics, AA illness characteristics, QOL (Skindex-16 AA), and daily impairment (Work Productivity and Activity Impairment). The association between patient demographics and illness variables, the Skindex-16 AA scores, and the Work Productivity and Activity Impairment scores were analyzed using regression analyses. The mean age of patients was 39 years (51% female). Self-reported severity of current AA was rated as mild (21%), moderate (54%), and severe (25%). The highest impairment was observed for the Skindex-16 AA emotions and the Work Productivity and Activity Impairment daily activity performance scores. Although the degree of scalp hair loss (physician Severity of Alopecia Tool score) was not predictive of QOL, patients' self-report of moderate or severe disease, sex (females more impacted), and eyebrow and eyelash involvement were predictors of diminished QOL, consistently and incrementally. The present results suggest patients' perception of severity as well as the presence of eyelash and eyebrow hair loss are also impactful and should be considered in defining the severity of disease.
引用
收藏
页码:2646 / +
页数:8
相关论文
共 50 条
  • [1] Alopecia areata [Alopecia areata]
    Von Felbert V.
    Merk H.F.
    Der Hautarzt, 2013, 64 (11): : 806 - 809
  • [2] Comorbidities in patients with alopecia areata
    Conic, Ruzica Z.
    Miller, Rose
    Piliang, Melissa
    Bergfeld, Wilma
    Mesinkovska, Natasha Atanaskova
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (04) : 755 - 757
  • [3] ANXIETY IN PATIENTS WITH ALOPECIA AREATA
    Kaaz, Karolina
    Puchalska, Agata
    Marcinow, Katarzyna
    Garbowska, Justyna
    Reich, Adam
    Szepietowski, Jacek C.
    ACTA DERMATO-VENEREOLOGICA, 2016, 96 : 137 - 137
  • [4] Retrospective Evaluation of Alopecia Areata Patients
    Gonul, Muzeyyen
    Gul, Ulker
    Piskin, Emine
    Cakmak, Seray Kulcu
    Soylu, Secil
    Kilic, Arzu
    Biyikli, Zeynep
    TURK DERMATOLOJI DERGISI-TURKISH JOURNAL OF DERMATOLOGY, 2011, 5 (02): : 43 - 47
  • [5] Thyroid Autoimmunity in Patients with Alopecia Areata
    Kasumagic-Halilovic, Emina
    ACTA DERMATOVENEROLOGICA CROATICA, 2008, 16 (03) : 123 - 125
  • [6] Hearing impairment in patients with alopecia areata
    Shakoei, Safoura
    Mohammadnia, Elahe
    Saedi, Babak
    Ghandi, Narges
    Khamisabadi, Saeedeh
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2024, 90 (02): : 158 - 162
  • [7] CORTICOSTEROID METABOLISM OF PATIENTS WITH ALOPECIA AREATA
    OWENS, DW
    SIMON, EL
    BROWN, H
    KNOX, JM
    ARCHIVES OF DERMATOLOGY, 1966, 93 (04) : 413 - +
  • [8] Psychiatric Symptoms in Patients with Alopecia Areata
    Ari, Burak
    Cenesizoglu, Erol
    Denli, Yasargul
    TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, 2011, 45 (04): : 203 - 205
  • [9] Prolactine levels in the patients with alopecia areata
    Gonul, M.
    Gul, U.
    Cakmak, S. K.
    Kilinc, C.
    Kilinc, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (11) : 1343 - 1344
  • [10] Efficacy of the diphenylcyclopropenoneimmunotherapy in patients with alopecia areata
    Todorova, A.
    Weidinger, S.
    Worret, W.
    Ring, J.
    ALLERGY, 2008, 63 : 197 - 197